|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2001-4-10
|
|
pubmed:abstractText |
Besides the low therapeutic index drug tolbutamide, there is no validated in vivo probe to assess the genetically determined CYP2C9 activity in humans. The in vitro CYP2C9-specific substrate diclofenac might be a valuable, well-tolerated probe candidate. In order to validate diclofenac as an in vivo CYP2C9 probe, we planned to show that urinary 4'-hydroxydiclofenac/diclofenac metabolic ratio (MR) would correlate to the apparent partial metabolic clearance of diclofenac into 4'-hydroxydiclofenac (Clmet).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0031-6970
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
56
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
793-7
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11294368-Adult,
pubmed-meshheading:11294368-Alleles,
pubmed-meshheading:11294368-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:11294368-Area Under Curve,
pubmed-meshheading:11294368-Aryl Hydrocarbon Hydroxylases,
pubmed-meshheading:11294368-Cytochrome P-450 Enzyme System,
pubmed-meshheading:11294368-Diclofenac,
pubmed-meshheading:11294368-Female,
pubmed-meshheading:11294368-Genotype,
pubmed-meshheading:11294368-Humans,
pubmed-meshheading:11294368-Male,
pubmed-meshheading:11294368-Middle Aged,
pubmed-meshheading:11294368-Steroid 16-alpha-Hydroxylase,
pubmed-meshheading:11294368-Steroid Hydroxylases,
pubmed-meshheading:11294368-Tablets, Enteric-Coated
|
|
pubmed:articleTitle |
Is diclofenac a valuable CYP2C9 probe in humans?
|
|
pubmed:affiliation |
Clinical Pharmacology Unit, Saint Antoine University Hospital School of Medicine, Paris, France.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
